Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1278081 | 1.00 | HTR2B (0.32) | HTR2BMAPK1PARP14JAK2JAK1 | |
| SCHEMBL1277734 | 0.92 | MAPK1 (0.31) | MAPK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL1277737 | 0.92 | MAPK1 (0.31) | MAPK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL1277657 | 0.91 | TDO2 (0.34) | HTR2B | |
| SCHEMBL1277661 | 0.91 | TDO2 (0.34) | HTR2B | |
| SCHEMBL1277340 | 0.91 | MAPK1 (0.30) | MAPK1 | |
| SCHEMBL1277343 | 0.91 | MAPK1 (0.30) | MAPK1 | |
| SCHEMBL1277924 | 0.90 | HTR2B (0.33) | HTR2B | |
| SCHEMBL1277923 | 0.90 | HTR2B (0.33) | HTR2B | |
| SCHEMBL1277719 | 0.89 | PARP14 (0.36) | HTR2BMAPK1PARP14JAK2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309586-B2 | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient | LG LIFE SCIENCES LTD. (KR) | 2012-11-13 | — | — | US | claimed |
| US-20120088760-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG CHEM, LTD. (KR) | 2012-04-12 | — | — | US | claimed |
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2010-10-21 | — | — | US | claimed |
| EP-2220081-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG Life Sciences Ltd. (KR) | 2010-08-25 | — | — | EP | claimed |
| WO-2009082152-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2009-07-02 | — | — | WO | claimed |
| US-8309586-B2 | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient | LG LIFE SCIENCES LTD. (KR) | 2012-11-13 | — | — | US | disclosed |
| US-20120088760-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG CHEM, LTD. (KR) | 2012-04-12 | — | — | US | disclosed |
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2010-10-21 | — | — | US | disclosed |
| EP-2220081-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG Life Sciences Ltd. (KR) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009082152-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088760-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | GCKR, GCK, GALK1 | HTR2B 4511/4885MAPK1 579/4885PARP14 3554/4885 |
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | GCK, GCKR, HK1 | HTR2B 4425/4885MAPK1 596/4885PARP14 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.